The Effect of Salmeterol on Eosinophil Function

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00214019
• Date of registration: 13/09/2005
• Primary sponsor: University of Wisconsin, Madison
• Public title: The Effect of Salmeterol on Eosinophil Function
• Scientific title: The Effect of Salmeterol on Eosinophil Function
• Date of first enrolment: November 2003
• Target sample size: 16
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00214019
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment

Countries of recruitment

United States

Contacts

• Name: William Busse, MD
• Affiliation: University of Wisconsin, Madison

Key inclusion & exclusion criteria

Inclusion Criteria:

- 18-55 years of age

- history of asthma symptoms for the previous 6 months

- FEV1 >75% of predicted

- positive prick skin test to cat, house dust mite or ragweed

Exclusion Criteria:

- history of life threatening asthma or anaphylaxis

- current smoker

- pregnant or breast-feeding

- evidence of an upper respiratory infection within 4 weeks of screening



Age minimum: 18 Years
Age maximum: 55 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Mild Allergic Asthma

Intervention(s)

Drug: salmeterol, fluticasone

Primary Outcome(s)

sputum eosinophils post antigen challenge

Secondary Outcome(s)

sputum eos pre antigen challenge, blood eos pre and post antigen challenge, methacholine PC20 post antigen challenge

Secondary ID(s)

H-2003-0469

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

GlaxoSmithKline